The μ-opioid receptor-mediated G_i/o protein and β-arrestin2 signaling pathways both contribute to morphine-induced...

Area of Science:

• Pharmacology
• Neuroscience
• Molecular Biology

Background:

• The μ-opioid receptor (MOR) signaling is complex, involving G protein and β-arrestin pathways.
• Current biased agonists aim to separate analgesia from side effects, but clinical issues persist.
• Understanding MOR phosphorylation is crucial for developing safer analgesics.

Purpose of the Study:

• To investigate the roles of specific MOR phosphorylation sites in mediating G protein and β-arrestin2 signaling.
• To assess the impact of interfering with these pathways on morphine-induced analgesia and side effects.
• To explore novel therapeutic strategies for mitigating opioid-related adverse events.

Main Methods:

• Design of five permeable peptides targeting MOR carboxyl-terminal S/T phosphorylation sites.
• In vitro cAMP inhibition assay to measure G protein activation.
• BRET assay to quantify β-arrestin2 recruitment.
• In vivo studies in mice to evaluate morphine-induced tolerance, respiratory inhibition, and constipation.

Main Results:

• Designed peptides modulated G protein and β-arrestin2 pathways when combined with morphine.
• β-arrestin2 pathway mediated morphine tolerance.
• G protein (G_io) signaling was linked to respiratory depression and constipation.
• Phosphorylation sites S363 and T370 were significantly associated with these side effects.

Conclusions:

• Specific MOR phosphorylation sites play distinct roles in mediating opioid effects and side effects.
• Targeting these sites offers a potential strategy for developing safer opioid analgesics.
• The designed peptides serve as valuable tools for further elucidating MOR signaling mechanisms.